Project Grant R21NS139533
Award Date 8/22/26
Completion Date 7/31/28
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
- The National Institute on Aging awarded the University of Arizona a cooperative agreement totaling $6,348,351 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a first-in-human Phase 1A randomized, placebo-controlled safety and tolerability study of PNA5, a novel glycosylated angiotensin-(1-7) peptide and selective MAS receptor agonist designed to treat vascular cognitive impairment and dementia (VCID) and Alzheimer's disease-related dementias (ADRD). The study will...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded Midwestern University $553,721 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to evaluate the efficacy and mechanisms of a novel manganese porphyrin compound in a Drosophila model of Parkinson's disease. The research measures brain levels of oxidized and...
- The National Institute on Aging awarded the University of Arizona $611,338 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop selective DYRK1A inhibitors for Alzheimer's disease treatment. The research targets dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a therapeutic intervention modulating tau, amyloid, and neuroinflammatory pathways in Alzheimer's disease. Prior work demonstrated that the DYRK1A inhibitor DYR533 improves behavioral and...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $540,901 on April 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate molecular mechanisms underlying dopamine signaling dysfunction in advanced Parkinson's disease. The research examines how striatal projection neurons become maladaptive during disease progression and why L-DOPA therapy loses efficacy over time. The work focuses...
- The National Institute of Neurological Disorders and Stroke awarded the University of Arizona $102,368 on June 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to characterize the brain's lymphatic drainage in an Alzheimer's disease rat model and investigate two therapies—manual lymphatic drainage and lymphaticovenous anastomosis—for repurposing to Alzheimer's disease treatment. The research addresses an unmet need in...
- The National Institute of Neurological Disorders and Stroke awarded The University of Texas Southwestern Medical Center $513,535 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to discover and develop small molecule positive allosteric modulators (PAMs) for the D2 dopamine receptor. The award funds structure-guided drug discovery using cryo-electron microscopy structures of the activated human D2 dopamine receptor...
- The National Institute of Neurological Disorders and Stroke awarded the University of Georgia Research Foundation $1,297,188 on May 8, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate neuroinflammatory epitranscriptomic mechanisms in Parkinson's disease. The research examines the role of the ALKBH5 demethylase enzyme in microglial neuroinflammatory responses triggered by alpha-synuclein aggregates, a hallmark...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $418,489 to the University of Florida on September 1, 2026, for exploration of potential treatments targeting alpha-synuclein in Parkinson's disease under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to develop novel therapeutics for Parkinson's disease,...
- The National Institute of Neurological Disorders and Stroke awarded San Diego Biomedical Research Institute $541,750 on May 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to discover noncanonical autophagy modulators for Alzheimer's disease and related dementias. The project establishes two complementary intracellular functional screening platforms to identify novel autophagy-activating molecules that restore proteostasis in...
- The National Institute of Neurological Disorders and Stroke awarded The Regents of the University of California, San Francisco $595,208 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Assistance Listing Project Grant R01NS148534). The award funds research investigating striatal synaptic plasticity mechanisms underlying cognitive dysfunction in Parkinson's disease. The project examines circuit- and synaptic-level...